Individual baseline characteristics and outcome of subjects with newly diagnosed AML (de novo or secondary to MDS), unfit for standard therapy
BST-236 dose, g/m2 per d . | No. of induction courses . | Age, y . | ECOG PS . | Prior MDS . | No. of prior HMA courses . | ELN cytogenetic risk score . | Molecular aberration . | Cytogenetics . | Baseline BM blasts, % . | Baseline PB blasts, % . | Baseline WBC, ×109/L . | Best response . | Survival, d . |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.8 | 2 | 80 | 1 | No | 0 | Adverse | FLT3+, NPM1+ | NK | 80 | 13 | 7.06 | CRp | 308 |
1.5 | 1 | 76 | 0 | Yes | 0 | Intermediate | IDH1+, NMP1+ | NK | 81 | 24 | 7.26 | Withdrawn* | 36 |
1.5 | 1 | 80 | 0 | Yes | 26 | Adverse | None | 5q− (+ complex karyotype) | 36 | 0 | 0.75 | Refractory | 13 |
2.3 | 1 | 83 | 2 | Yes | 0 | Intermediate | None | NK | 90 | ND | 0.75 | PR | 79 |
2.3 | 1 | 73 | 0 | Yes | 5 | Intermediate | None | NK | 58 | 53 | 2.41 | Refractory | 18 |
2.3 | 1 | 78 | 0 | No | 0 | Adverse | FLT3+ | NK | 43 | 30 | 2.50 | Refractory | 28 |
2.3 | 1 | 70 | 1 | Yes | 5 | Intermediate | None | NK | 22 | 9 | 1.86 | CR | 623 |
4.5 | 1 | 72 | 1 | Yes | 0 | Adverse | FLT3+, NPM1+ | NK | 85 | ND | 11.00 | Refractory | 207 |
4.5 | 1 | 77 | 2 | Yes | 10 | Adverse | None | Del 7 | 30 | ND | 4.30 | CR | 397 |
6 | 1 | 88 | 1 | Yes | 9 | Favorable | NPM1+ | NK | 100 | 85 | 61.82 | Refractory | 88 |
6 | 2 | 81 | 1 | No | 0 | Adverse | None | Complex karyotype | 100 | 40 | 24.55 | CR | 195 |
BST-236 dose, g/m2 per d . | No. of induction courses . | Age, y . | ECOG PS . | Prior MDS . | No. of prior HMA courses . | ELN cytogenetic risk score . | Molecular aberration . | Cytogenetics . | Baseline BM blasts, % . | Baseline PB blasts, % . | Baseline WBC, ×109/L . | Best response . | Survival, d . |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.8 | 2 | 80 | 1 | No | 0 | Adverse | FLT3+, NPM1+ | NK | 80 | 13 | 7.06 | CRp | 308 |
1.5 | 1 | 76 | 0 | Yes | 0 | Intermediate | IDH1+, NMP1+ | NK | 81 | 24 | 7.26 | Withdrawn* | 36 |
1.5 | 1 | 80 | 0 | Yes | 26 | Adverse | None | 5q− (+ complex karyotype) | 36 | 0 | 0.75 | Refractory | 13 |
2.3 | 1 | 83 | 2 | Yes | 0 | Intermediate | None | NK | 90 | ND | 0.75 | PR | 79 |
2.3 | 1 | 73 | 0 | Yes | 5 | Intermediate | None | NK | 58 | 53 | 2.41 | Refractory | 18 |
2.3 | 1 | 78 | 0 | No | 0 | Adverse | FLT3+ | NK | 43 | 30 | 2.50 | Refractory | 28 |
2.3 | 1 | 70 | 1 | Yes | 5 | Intermediate | None | NK | 22 | 9 | 1.86 | CR | 623 |
4.5 | 1 | 72 | 1 | Yes | 0 | Adverse | FLT3+, NPM1+ | NK | 85 | ND | 11.00 | Refractory | 207 |
4.5 | 1 | 77 | 2 | Yes | 10 | Adverse | None | Del 7 | 30 | ND | 4.30 | CR | 397 |
6 | 1 | 88 | 1 | Yes | 9 | Favorable | NPM1+ | NK | 100 | 85 | 61.82 | Refractory | 88 |
6 | 2 | 81 | 1 | No | 0 | Adverse | None | Complex karyotype | 100 | 40 | 24.55 | CR | 195 |
ND, not done; NK, normal karyotype; PB, peripheral blood; PR, partial response; WBC, white blood cells.
Withdrawn on day 2 due to pneumonia.